Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen

Prostate

Volumn 61, Issue 1, 2004, Pages 1-11

  Huang, Xianming ^a   Bennett, Mary ^a   Thorpe, Philip E ^a  

^a NONE

Author keywords

Immunotoxin; Monoclonal antibody; Prostate cancer; Prostate specific membrane antigen; Vascular endothelium

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E6; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RICIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; RICIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4143132205     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20074     Document Type: Article

References (35)

1. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-1443.
2. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-4789.
3. Hisatomi H, Nagao K, Kawakita M, Matsuda T, Hirata H, Yamamoto S, Nakamoto T, Harasawa H, Kaneko N, Hikiji K, Tsukada Y. Detection of circulating prostate tumor cells: Alternative spliced variant of PSM induced false-positive result. Int J Mol Med 2002;10:619-622.
4. Weissensteiner T. Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM). Nucleic Acids Res 1998;26:687.
5. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
6. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
7. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
8. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
9. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
10. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-2324.
11. Wright GL Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
12. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82:2256-2261.
13. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
14. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
15. 111indium- labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-1955.
16. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159: 2041-2047.
17. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
18. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
19. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-78.
20. Michaels EK, Blend MICH, Quintana JC. (111) Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol 1999;161:597-598.
21. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001;12:117-123.
22. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: Prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001;61:5857-5860.
23. Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. The Prostate 2003;55:308-316.
24. Moser AR, Hegge LF, Cardiff RD. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Cancer Res 2001;61:3480-3485.
25. Brekken RA, Huang X, King S, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998;58:1952-1959.
26. Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA 1993;90:8977-8981.
27. Thorpe PE, Ross WC. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 1982;62:119-158.
28. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232-242.
29. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
30. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57:1179-1183.
31. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-4060.
32. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61:2008-2014.
33. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr., Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-6100.
34. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9-23.
35. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El Sheikh A, Vessella R, Edgington TS. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002;62:5470-5475.